Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of combining oblimersen with imatinib mesylate in
treating patients who have chronic myelogenous leukemia that has not responded to previous
treatment with imatinib mesylate. Imatinib mesylate may stop the growth of cancer cells by
blocking the enzymes necessary for cancer cell growth. Oblimersen may help imatinib mesylate
kill more cancer cells by making cancer cells more sensitive to the drug.